Tamoxifen Inhibits TGF-β-Mediated Activation of Myofibroblasts by Blocking Non-Smad Signaling Through ERK1/2

Journal of Cellular Physiology

Volumn 230, Issue 12, 2015, Pages 3084-3092

  Carthy, Jon M ^a   Sundqvist, Anders ^a   Heldin, Angelos ^a   van Dam, Hans ^a,b   Kletsas, Dimitris ^c   Heldin, Carl Henrik ^a   Moustakas, Aristidis ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ALPHA SMOOTH MUSCLE ACTIN; CALPONIN; COLLAGEN GEL; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; PROTEIN KINASE B; SM 22ALPHA PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TAMOXIFEN; TRANSCRIPTION FACTOR FRA 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FOSL2 PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL ACTIVATION; CELL CONTRACTION ASSAY; CELL LYSATE; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DENSITOMETRY; ENZYME PHOSPHORYLATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; MYOFIBROBLAST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SURFACE AREA; WESTERN BLOTTING; BREAST; CELL DIFFERENTIATION; CELL LINE; CELL SHAPE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; METABOLISM; RNA INTERFERENCE; SKIN;

BIOLOGICAL MARKERS; BREAST; CELL DIFFERENTIATION; CELL LINE; CELL SHAPE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOS-RELATED ANTIGEN-2; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOFIBROBLASTS; PHENOTYPE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN; TAMOXIFEN; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84939863511     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25049     Document Type: Article

References (39)

1. Babu RL, Naveen Kumar M, Patil RH, Devaraju KS, Ramesh GT, Sharma SC. 2013. Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: Role of c-Jun, c-Fos, and Fra-1 in cell cycle regulation. Mol Cell Biochem 380:143-151.
2. Bartram U, Speer CP. 2004. The role of transforming growth factor β in lung development and disease. Chest 125:754-765.
3. Buck MB, Pfizenmaier K, Knabbe C. 2004. Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-β pathways in human breast cancer cells. Mol Endocrinol 18:1643-1657.
4. Caraci F, Gili E, Calafiore M, Failla M, La Rosa C, Crimi N, Sortino MA, Nicoletti F, Copani A, Vancheri C. 2008. TGF-β1 targets the GSK-3β/β-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res 57:274-282.
5. Cherlet T, Murphy LC. 2007. Estrogen receptors inhibit Smad3 transcriptional activity through Ap-1 transcription factors. Mol Cell Biochem 306:33-42.
6. Degreef I, Tejpar S, Sciot R, De Smet L. 2014. High-dosage tamoxifen as neoadjuvant treatment in minimally invasive surgery for Dupuytren disease in patients with a strong predisposition toward fibrosis: A randomized controlled trial. J Bone Joint Surg Am 96:655-662.
7. Delle H, Rocha JR, Cavaglieri RC, Vieira JM, Jr., Malheiros DM, Noronha IL. 2012. Antifibrotic effect of tamoxifen in a model of progressive renal disease. J Am Soc Nephrol 23:37-48.
8. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. 1993. Transforming growth factor-β 1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122:103-111.
9. Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V, Idarraga MH, Kenner L, Wagner EF. 2008. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA 105:10525-10530.
10. Gallo MA, Kaufman D. 1997. Antagonistic and agonistic effects of tamoxifen: Significance in human cancer. Semin Oncol 24:S1-71-S71-S80.
11. Gioni V, Karampinas T, Voutsinas G, Roussidis AE, Papadopoulos S, Karamanos NK, Kletsas D. 2008. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts. Mol Cancer Res 6:706-714.
12. Goto N, Hiyoshi H, Ito I, Iida K, Nakajima Y, Nagasawa K, Yanagisawa J. 2014. Identification of a novel compound that suppresses breast cancer invasiveness by inhibiting transforming growth factor-β signaling via estrogen receptor α. J Cancer 5:336-343.
13. Goto N, Hiyoshi H, Ito I, Tsuchiya M, Nakajima Y, Yanagisawa J. 2011. Estrogen and antiestrogens alter breast cancer invasiveness by modulating the transforming growth factor-β signaling pathway. Cancer Sci 102:1501-1508.
14. Hashimoto S, Gon Y, Takeshita I, Matsumoto K, Maruoka S, Horie T. 2001. Transforming growth Factor-β1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 163:152-157.
15. Hinz B, Gabbiani G. 2010. Fibrosis: Recent advances in myofibroblast biology and new therapeutic perspectives. F1000 Biol Rep 2:78.
16. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. 2007. The myofibroblast: One function, multiple origins. Am J Pathol 170:1807-1816.
17. Hu Y, Peng J, Feng D, Chu L, Li X, Jin Z, Lin Z, Zeng Q. 2006. Role of extracellular signal-regulated kinase, p38 kinase, and activator protein-1 in transforming growth factor-β1-induced α smooth muscle actin expression in human fetal lung fibroblasts in vitro. Lung 184:33-42.
18. Huang JW, Yen CJ, Wu HY, Chiang CK, Cheng HT, Lien YC, Hung KY, Tsai TJ. 2011. Tamoxifen downregulates connective tissue growth factor to ameliorate peritoneal fibrosis. Blood Purif 31:252-258.
19. Ito I, Hanyu A, Wayama M, Goto N, Katsuno Y, Kawasaki S, Nakajima Y, Kajiro M, Komatsu Y, Fujimura A, Hirota R, Murayama A, Kimura K, Imamura T, Yanagisawa J. 2010. Estrogen inhibits transforming growth factor β signaling by promoting Smad2/3 degradation. J Biol Chem 285:14747-14755.
20. Kim D, Lee AS, Jung YJ, Yang KH, Lee S, Park SK, Kim W, Kang KP. 2014. Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor α-mediated transforming growth factor-β1/Smad signaling pathway. Nephrol Dial Transplant 29:2043-2053.
21. Lee JH, Park SM, Kim OS, Lee CS, Woo JH, Park SJ, Joe EH, Jou I. 2009. Differential SUMOylation of LXRα and LXRβ mediates transrepression of STAT1 inflammatory signaling in IFN-γ-stimulated brain astrocytes. Mol Cell 35:806-817.
22. Li L, Asteriou T, Bernert B, Heldin CH, Heldin P. 2007. Growth factor regulation of hyaluronan synthesis and degradation in human dermal fibroblasts: Importance of hyaluronan for the mitogenic response of PDGF-BB. Biochem J 404:327-336.
23. Liu X, Sun SQ, Hassid A, Ostrom RS. 2006. CAMP inhibits transforming growth factor-β-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in cardiac fibroblasts. Mol Pharmacol 70:1992-2003.
24. Lonard DM, Smith CL. 2002. Molecular perspectives on selective estrogen receptor modulators (SERMs): Progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67:15-24.
25. Luga V, Wrana JL. 2013. Tumor-stroma interaction: Revealing fibroblast-secreted exosomes as potent regulators of Wnt-planar cell polarity signaling in cancer metastasis. Cancer Res 73:6843-6847.
26. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F. 2001. Cross-talk between transforming growth factor-β and estrogen receptor signaling through Smad3. J Biol Chem 276:42908-42914.
27. Mikulec AA, Hanasono MM, Lum J, Kadleck JM, Kita M, Koch RJ. 2001. Effect of tamoxifen on transforming growth factor β1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg 3:111-114.
28. Mousavi SR, Raaiszadeh M, Aminseresht M, Behjoo S. 2010. Evaluating tamoxifen effect in the prevention of hypertrophic scars following surgical incisions. Dermatol Surg 36:665-669.
29. Moustakas A, Heldin CH. 2009. The regulation of TGFβ signal transduction. Development 136:3699-3714.
30. Otranto M, Sarrazy V, Bonte F, Hinz B, Gabbiani G, Desmouliere A. 2012. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr 6:203-219.
31. Ozener C, Kiris S, Lawrence R, Ilker Y, Akoglu E. 1997. Potential beneficial effect of tamoxifen in retroperitoneal fibrosis. Nephrol Dial Transplant 12:2166-2168.
32. Ramirez AM, Shen Z, Ritzenthaler JD, Roman J. 2006. Myofibroblast transdifferentiation in obliterative bronchiolitis: TGF-β signaling through smad3-dependent and -independent pathways. Am J Transplant 6:2080-2088.
33. Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zerr P, Palumbo K, Zwerina J, Nevskaya T, Gay S, Distler O, Schett G, Distler JH. 2010. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 62:280-290.
34. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. 1998. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937.
35. Shimoda M, Principe S, Jackson HW, Luga V, Fang H, Molyneux SD, Shao YW, Aiken A, Waterhouse PD, Karamboulas C, Hess FM, Ohtsuka T, Okada Y, Ailles L, Ludwig A, Wrana JL, Kislinger T, Khokha R. 2014. Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state. Nat Cell Biol 16:889-901.
36. Stubert J, Dieterich M, Gerber B. 2014. Medical prevention of breast cancer. Breast Care (Basel) 9:391-396.
37. van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. 2006. Brief communication: Tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 144:101-106.
38. Yoldas O, Karaca T, Bilgin BC, Yilmaz OH, Simsek GG, Alici IO, Uzdogan A, Karaca N, Akin T, Yoldas S, Akbiyik F. 2015. Tamoxifen citrate: A glimmer of hope for silicosis. J Surg Res 193:429-434.
39. Zhao WJ, Wang K. 2013. NGX6 expression improves the sensitivity of tamoxifen-resistant MCF-7 cells through modulation of the Smad signaling pathway. Int J Oncol 42:2060-2068.